October FDA Approvals Bring Advances Across 5 Specialties
October FDA approvals include Novartis' remibrutinib for dermographism, Teva's once-monthly olanzapine for schizophrenia, Genentech's satralizumab for thyroid eye disease, GSK's bepirovirsen for chronic HBV, and AbbVie's risankizumab for Crohn disease. Each approval offers new treatment options and was based on clinical trial data.
How this was made
The 30-second read
Why it matters
These approvals introduce new therapeutic options, potentially expanding market share and revenue for each issuer.
Market read
Multiple first‑in‑class FDA approvals could drive short‑term upside in biotech equities and reinforce sector momentum.
What to watch
Reimbursement negotiations and insurance coverage decisions may delay revenue realization.
Background
October saw a wave of FDA approvals outside oncology, covering dermatology, psychiatry, ophthalmology, hepatology, and gastroenterology.
Ticker impact
FDA approved Novartis' remibrutinib (Rhapsido) for symptomatic dermographism on Oct 7.
likely upward pressure as market prices in new indication.
First-in-class approval provides revenue growth and market share opportunity.
FDA approved Teva's once‑monthly subcutaneous olanzapine (Weltruza) for schizophrenia on Oct 9.
moderate upside as investors value new product line.
Unique delivery method differentiates from competitors, supporting pricing power.
FDA approved GSK's bepirovirsen (Hibsago) for chronic hepatitis B without cirrhosis on Oct 20.
upward pressure as investors price in potential cure‑based market.
High unmet need and functional‑cure claim drive strong commercial potential.
FDA approved AbbVie's SC induction regimen of risankizumab (Skyrizi) for Crohn disease on Oct 23.
moderate upside as market values expanded indication.
SC induction may increase patient uptake and market share.
Market effects
Strengthens biotech/pharma sector with multiple first‑in‑class FDA approvals across specialties.
U.S. biotech stocks may see broad gains; European peers could be affected by competitive pressure.
Highlights continued pipeline productivity, supporting global healthcare investment sentiment.
Counterpoint
If post‑approval sales lag or pricing pressures emerge, stocks could underperform expectations.
Key entities
- CompanyNovartis
Pharmaceutical giant receiving first‑in‑class SD treatment approval.
- CompanyTeva Pharmaceuticals
Developer of the first once‑monthly SC olanzapine injection.
- CompanyGenentech (Roche)
Provider of at‑home SC therapy for thyroid eye disease.
- CompanyGSK
Introduced first antisense HBV therapy.
- CompanyAbbVie
Expanded SC induction for Crohn disease.
